Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”,
“Company”, “We” or “Us”), today announced the completion of its
initial CAR-T NXC-201 engineering batch at its U.S. manufacturing
site. This represents an important step forward in the planned U.S.
expansion of the Company’s ongoing Phase 1b/2a NEXICART-1
(NCT04720313) study of its novel BCMA-targeted chimeric antigen
receptor T (CAR-T) cell therapy NXC-201. This milestone is
completed following the selection of a U.S. GMP manufacturer in
February 2023 and commencement of U.S. engineering batches in May
2023.
“The completion of our first U.S. engineering batch is a
significant step towards expanding our Phase 1b/2a NEXICART
clinical trial to the United States as we work to bring NXC-201 to
American patients in need,” said Ilya Rachman, M.D. Ph.D. Chief
Executive Officer of Immix Biopharma. “NXC-201 is the first CAR-T
being developed in AL Amyloidosis. We believe that our 100% overall
response rate in relapsed/refractory AL amyloidosis patients who
have received a median 6 lines of therapies that failed to halt
disease progression prior to receiving NXC-201 gives hope to AL
amyloidosis patients with limited treatment options. In
relapsed/refractory multiple myeloma, our NXC-201 92% overall
response rate similarly could provide a viable option for patients
with limited treatment options.”
“Today, 95% of U.S. medical centers are unable to offer CAR-T
cell therapy. In the 5% of U.S medical centers that do offer CAR-T
treatment, patients are hospitalized for a current market-standard
14 days,” said Gabriel Morris, Chief Financial Officer of Immix
Biopharma. “NXC-201 has been trialed in 58 patients, demonstrating
a 1-2 day median side-effect duration and a median day 0-1 onset,
which offers potential to reduce hospitalization costs up to 80%,
and potentially enable dosing in the 95% of U.S. medical centers
today unable to offer CAR-T cell therapy.”
About NXC-201
NXC-201 (formerly HBI0101) is a BCMA-targeted investigational
chimeric antigen receptor T (CAR-T) cell therapy that is being
studied in a comprehensive clinical development program for the
treatment of patients with relapsed/refractory multiple myeloma and
relapsed/refractory AL amyloidosis across 58 patients.
About NEXICART-1
NEXICART-1 (NCT04720313) is an ongoing Phase 1b/2a, open-label
study evaluating the safety and efficacy of NXC-201 (formerly
HBI0101), in adults with relapsed/refractory multiple myeloma and
relapsed/refractory AL amyloidosis.
The primary objective of the Phase 1b portion of the study was
to characterize the safety and confirm the recommended Phase 2 dose
(RP2D) and Phase 2 dose of NXC-201. The Phase 2 portion of the
study will evaluate the efficacy and safety of NXC-201 in
relapsed/refractory Multiple Myeloma according to the International
Myeloma Working Group (IMWG) Uniform Response Criteria and in
relapsed/refractory AL Amyloidosis according to consensus
recommendations.
The Phase 1b portion of the ongoing Phase 1b/2a clinical trial
has been successful in determining the recommended Phase 2 dose
(RP2D) of 800 million CAR+T cells. Nexcella plans to submit an IND
application to the FDA for a Phase 1b/2 of NXC-201 in
relapsed/refractory multiple myeloma and relapsed/refractory AL
amyloidosis in order to expand the ongoing clinical trial to the
U.S. The expected primary endpoint for the Phase 2 portion of the
ongoing Phase 1b/2a clinical trial of NXC-201 in
relapsed/refractory multiple myeloma is overall response rate and
duration of response. Nexcella plans to submit data to the FDA in
relapsed/refractory multiple myeloma once 100 patients are treated
with NXC-201. The expected primary endpoint for NXC-201 in
relapsed/refractory AL Amyloidosis is overall response rate.
Nexcella plans to submit data to the FDA in relapsed/refractory AL
amyloidosis once 30-40 patients are treated with NXC-201.
About AL Amyloidosis
AL amyloidosis is a rare systemic disorder caused by an
abnormality of plasma cells in the bone marrow. Misfolded amyloid
proteins produced by plasma cells cause buildup in and around
tissues, nerves and organs, gradually affecting their function.
This can cause progressive and widespread organ damage, and high
mortality rates.
AL amyloidosis affects roughly 30,000 – 40,000 patients in total
throughout the U.S. and Europe, and it is estimated that there are
approximately 3,000 – 4,000 new cases of AL amyloidosis annually in
the U.S. The annual global incidence of AL Amyloidosis is ~15,000
patients.
The Amyloidosis market was $3.6 billion in 2017, expected to
reach $6 billion in 2025, according to Grand View Research.
About Multiple Myeloma
Multiple myeloma (“MM”) is an incurable blood cancer of plasma
cells that starts in the bone marrow and is characterized by an
excessive proliferation of these cells. Despite initial remission,
unfortunately, most patients are likely to relapse. There are
35,730 patients in the United States diagnosed with MM each year.
Prognosis for patients who do not respond to or relapse after
treatment with standard therapies, including protease inhibitors
and immunomodulatory agents remains poor.
The $13.9 billion Multiple Myeloma market in 2017 is expected to
reach $28.7 billion in 2027 according to Wilcock, et al. Nature
Reviews.
About Nexcella, Inc.
Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq:
IMMX), is a Los Angeles, CA based clinical-stage biopharmaceutical
company engaged in the discovery and development of novel cell
therapies for oncology and other indications. Our lead candidate,
next generation BCMA-targeted CAR-T NXC-201 for relapsed/refractory
multiple myeloma and relapsed/refractory AL amyloidosis has
produced 92% and 100% response rates in each indication,
respectively, as of February 9, 2023 across 58 patients. We believe
NXC-201 has potential to be the world’s first outpatient CAR-T. Our
N-GENIUS platform allows us to discover, develop, and manufacture
cutting-edge cell therapies for patients in need. To learn more
about Nexcella, Inc. visit us at www.nexcella.com.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a
clinical-stage biopharmaceutical company pioneering a novel class
of CAR-T cell therapies and Tissue-Specific Therapeutics (TSTx)
targeting oncology and immuno-dysregulated diseases with >75
patients treated to-date. Our lead cell therapy asset is NXC-201 in
relapsed/refractory multiple myeloma and relapsed/refractory AL
Amyloidosis, which we believe could be the world’s first
out-patient CAR-T. Our lead TSTx asset IMX-110, currently in Phase
1b/2a clinical trials as a monotherapy and IMMINENT-01 combination
clinical trial with BeiGene’s anti-PD-1 antibody tislelizumab,
holds Orphan Drug Designation (ODD) and Rare Pediatric Disease
Designation (RPDD) by the FDA. ImmixBio subsidiary Nexcella, Inc
develops CAR-T NXC-201 for multiple myeloma and AL amyloidosis,
with 92% and 100% response rates in each indication, respectively,
as of February 9, 2023, currently being trialed in NEXICART-1.
Learn more at www.immixbio.com.
Forward Looking Statements
This press release contains “forward-looking statements”
Forward-looking statements reflect our current view about future
events. When used in this press release, the words “anticipate,”
“believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the
negative of these terms and similar expressions, as they relate to
us or our management, identify forward-looking statements. Such
statements, include, but are not limited to, statements contained
in this press release relating to our business strategy, our future
operating results and liquidity and capital resources outlook.
Forward-looking statements are based on our current expectations
and assumptions regarding our business, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict. Our actual
results may differ materially from those contemplated by the
forward-looking statements. They are neither statements of
historical fact nor guarantees of assurance of future performance.
We caution you therefore against relying on any of these
forward-looking statements. Important factors that could cause
actual results to differ materially from those in the
forward-looking statements include, without limitation, our ability
to raise capital to fund continuing operations; our ability to
protect our intellectual property rights; the impact of any
infringement actions or other litigation brought against us;
competition from other providers and products; our ability to
develop and commercialize products and services; changes in
government regulation; our ability to complete capital raising
transactions; and other factors relating to our industry, our
operations and results of operations. Actual results may differ
significantly from those anticipated, believed, estimated,
expected, intended or planned including: the uncertainties related
to market conditions and other factors described more fully in the
section entitled ‘Risk Factors’ in Immix Biopharma’s Annual Report
on Form 10-K for the year ended December 31, 2022, and other
periodic reports filed with the Securities and Exchange Commission.
Any forward-looking statements contained in this press release
speak only as of the date hereof, and Immix Biopharma, Inc.
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
Factors or events that could cause our actual results to differ
may emerge from time to time, and it is not possible for us to
predict all of them. We cannot guarantee future results, levels of
activity, performance or achievements.
ContactsStern Investor RelationsAlex
LoboManaging DirectorAlex.lobo@sternir.com
Company Contactirteam@immixbio.com
Immix Biopharma (NASDAQ:IMMX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Immix Biopharma (NASDAQ:IMMX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024